ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PTCT / news
ERAS (33) TVTX (52) COGT (42) DNTH (39) ⌘ Pro Terminal →

Why PTCT Stock advanced +1.52% Today — RQD Quant Desk Flash

$60.88 +1.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $60.93

PTC Therapeutics Inc. (PTCT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $5.01B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PTCT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PTCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, PTC Therapeutics Inc. (NASDAQ: PTCT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $60.88 (+1.52% 1D, market cap $5.01B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, PTCT ranks #137 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PTCT compare to ERAS and TVTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTCT carries a Roarable C (63/100 RQD), trailing P/E of 7.9x, gross margin of —, and ROIC of 85.0%. By comparison, ERAS (Erasca Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.02B) and TVTX (Travere Therapeutics Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -13.0%, cap $4.75B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PTCT?
▼

Per PTCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001070081), PTC Therapeutics Inc. generated $1.73B in revenue (+114.5% YoY), $683.0M in net income, and $702.3M in free cash flow against $2.90B in total assets and $1.40B in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $60.93 (+0.08%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 40.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510063
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C+ · Rk D+
Cash (16)Whales (5)SEC (12)Macro (11)CEO (19)
Each axis scored 0–20
12M PRICE TARGET CONE+2.3% Base Target
$95 Bull$62 Base$49 Bear
📬 FREE PTCT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PTCT)Realized 20D OHLCV Swing Band: ±8.2%
Deterministic 5-Pillar Attribution (63/100 Composite)
🔍 WHY PTCT SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (30% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 40.6% FCF Margin ($702.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$59.67+4.9% Next Q
Q2 (-2Q)
58
Grade C$62.62+0.6% Next Q
Q3 (-1Q)
60
Grade C$63.02-3.4% Next Q
Current
63
Grade C$60.88+0.9% Hist 90D α
Trajectory: C (55) → C (63)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PTCT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, PTCT faces multiple-compression risk if 7.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($64.85) or 200D SMA ($70.51) invalidates the momentum regime and cuts Target Base ($62.25) toward Bear Floor ($48.55).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PTCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PTCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 63%NO 37%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why PTCT Stock advanced +1.52% Today — RQD Quant Desk Flash

PTC Therapeutics Inc. (PTCT) advanced +1.52% to $60.88, trading at 6% of its 52-week range ($58.8 – $90.87). Solid steady margins (85% return on capital), mixed timing at 8x P/E—hold if owned, no rush to chase.

  • ▸Technical Tape: Trading at 6% of its 52-week range ($58.8 – $90.87) with RSI-14 at 43.2 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±8.2% around $60.88 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $702.3M annual free cash flow.
Live PTCT Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PTCT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PTCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.04%▼ DESCENDING CHANNEL
2026-11-03O $64.46H $64.46L $59.97C $60.88VOL 2.36M
RES: $64.38SUP: $57.14SMA50: $64.85SMA200: $70.51
$93.11$83.81$74.51$65.21$55.91RES $64.38SUP $57.14$60.882026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PTCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PTCT Butterfly Map → + Track PTCT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-5.7%/yr Implied 5Y Growth

vs. +114.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PTCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PTCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PTCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PTCT)

Health Care Rank #137 of 1015 ⚔️ ERAS vs PTCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PTCT vs. ERAS, TVTX, COGT, DNTH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PTC Therapeutics Inc. (PTCT) ranks #137 by composite RQD confidence (63/100, grade C) and #163 by equity capitalization ($5.01B). Within this direct 5-issuer industry benchmark cohort, PTCT leads on earnings valuation at 7.9x trailing P/E, while PTCT leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PTCT currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PTCT ACTIVE
PTC Therapeutics Inc.
C 63/100 7.9x — 85.0% +1.52% $5.01B Benchmark Subject
ERAS
Erasca Inc.
E 33/100 — — -35.0% -2.09% $5.02B /eras-vs-ptct →
TVTX
Travere Therapeutics Inc.
D+ 52/100 — 96.0% -13.0% -2.24% $4.75B /tvtx-vs-ptct →
COGT
Cogent Biosciences Inc.
D- 42/100 — — -35.0% -4.16% $5.38B /cogt-vs-ptct →
DNTH
Dianthus Therapeutics Inc.
D- 39/100 — — -30.7% -0.16% $4.61B /dnth-vs-ptct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001070081 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PTC Therapeutics Inc. (PTCT) reported GAAP revenue of $1.73B (+114.5% vs. FY2024 revenue of $806.8M , and +84.5% cumulative change since FY2023) , GAAP net income of $683.0M, operating cash flow of $711.2M, and free cash flow of $702.3M (+715.1% YoY). On the balance sheet, PTCT closed FY2025 with $2.90B in total assets against $1.40B in total debt (Altman Z-Score: 1.73, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.73B $683.0M $711.2M $702.3M $2.90B $1.40B
FY2024 (FY) 2024-12-31 $806.8M -$363.3M -$107.7M -$114.2M $1.71B $285.4M
FY2023 (FY) 2023-12-31 $937.8M -$626.6M -$158.4M -$200.6M $2.96B $692.4M

3. PTCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PTCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PTC Therapeutics Inc. (NASDAQ: PTCT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $60.88 (+1.52% 1D, market cap $5.01B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, PTCT ranks #137 in composite RQD confidence.

How does PTCT compare to ERAS and TVTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTCT carries a Roarable C (63/100 RQD), trailing P/E of 7.9x, gross margin of —, and ROIC of 85.0%. By comparison, ERAS (Erasca Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.02B) and TVTX (Travere Therapeutics Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -13.0%, cap $4.75B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PTCT?

Per PTCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001070081), PTC Therapeutics Inc. generated $1.73B in revenue (+114.5% YoY), $683.0M in net income, and $702.3M in free cash flow against $2.90B in total assets and $1.40B in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PTCT trading relative to its 50-day, 200-day, and 52-week technical levels?

PTCT last traded at $60.88 (+1.52% on volume of 1,339,295 shares), positioning the stock -6.12% below its 50-day simple moving average ($64.85) and -13.66% below its 200-day simple moving average ($70.51). Across its 52-week range of $58.80 to $90.87, PTCT sits at the 6.5% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($55.89 to $65.87).

Direct Sub-Reports: PTCT RQD Cockpit PTCT 12M Forecast PTCT Earnings & Move PTCT Dividends & DRIP PTCT Insiders & 13F PTCT Whale Options PTCT Profit Sankey PTCT News & Why
ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ SEC XBRL & RQD VERIFIED

PTCT — PTC Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PTC Therapeutics Inc. (PTCT) earns a live Roarable RQD composite score of 63/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $60.88 (+1.52% 1D, market capitalization $5.01B).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 85.0%, gross margin of —, operating margin of 50.1%, and free cash flow yield of 13.05%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (19/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (12/20): Incorporates a 1.15x equity beta, Altman Z-Score of 1.73, Piotroski F-Score of 9/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

PTC Therapeutics Inc. (PTCT) is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile identifies the company as a biotechnology issuer with a market capitalization of $5.4B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PTC Therapeutics Inc. (PTCT) reported $1.73B in annual revenue (up from $806.8M in FY2024, +114.5% YoY) and $683.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($937.8M revenue, -$626.6M net income) through FY2025, PTCT scaled operating cash flow to $711.2M and free cash flow to $702.3M, backed by $2.90B in total assets against $1.40B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 63/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $58.80 – $90.87 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh 7.9x trailing P/E and 6.5x EV/EBITDA against 50.1% operating margins and a 1.15x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream or downstream dependencies, sector correlation coefficients, or 2nd-order bottlenecks. A prospective investor should note that the reported Q3 loss headline and the record-revenue headline conflict, and that the source does not supply the underlying mechanism; the beta of 1.15 is the only sector-sensitivity figure provided.

  • Key Question #1: Can PTCT sustain or expand its 50.1% operating margin and 85.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.73B and free cash flow of $702.3M, how will capital allocation balance growth reinvestment against $1.40B in total debt?
  • Key Question #3: How sensitive is PTCT's 6.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.15x)?

PTCT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PTC Therapeutics Inc. (PTCT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PTCT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PTCT Bull vs. Bear Conversation Board — What's Your Call at $60.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PTCT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PTCT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $70.16 (+17.0%)
📌 Pinned Debate

Reported FY 2025 operating income of $866.9M and an 85% ROIC underpin a 13.05% FCF yield and a 6.6 forward P/E.

The street is overcomplicating PTC Therapeutics Inc. (PTCT). Reported FY 2025 operating income of $866.9M and an 85% ROIC underpin a 13.05% FCF yield and a 6.6 forward P/E.. With an RQD score of 63/100 (C) and Forensic Balance Sheet at 12/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $64.77.

EarningsSniper 🐂 BULL

Both sides have a point here — PTCT's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $46.18 (-23.0%)
Spot @ $59.97

A Q3 results-return-to-loss headline, a 1.73 Altman Z-Score, and FY 2025 debt of $1.40B exceeding cash of $984.6M.

I respect the product at PTC Therapeutics Inc., but the stock at $59.97 is a different story. A Q3 results-return-to-loss headline, a 1.73 Altman Z-Score, and FY 2025 debt of $1.40B exceeding cash of $984.6M.. FCF yield is 13.05% and RQD sits at 63/100 (C) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE